Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

27.99 -2.17 (-7.19%)

Streaming Delayed Price Updated: 3:11 PM EDT, Apr 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity ↗

March 10, 2025

Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects.

Via Benzinga

Beam Therapeutics Announces Pricing of Underwritten Offering

March 10, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

March 10, 2025

From Beam Therapeutics

Via GlobeNewswire

Analyst Expectations For Beam Therapeutics's Future ↗

February 27, 2025

Via Benzinga

(BEAM) - Analyzing Beam Therapeutics's Short Interest ↗

January 31, 2025

Via Benzinga

Demystifying Beam Therapeutics: Insights From 4 Analyst Reviews ↗

January 29, 2025

Via Benzinga

Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14% ↗

March 04, 2025

Via Benzinga

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

February 25, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

February 24, 2025

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies ↗

February 22, 2025

Via Benzinga

Breaking Down Beam Therapeutics: 5 Analysts Share Their Views ↗

November 06, 2024

Via Benzinga

Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday ↗

February 15, 2025

Cathie Wood-led Ark Invest made trades involving IRDM, TWST, PD, BEAM, ROKU, and IBTA.

Via Benzinga

Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday ↗

February 14, 2025

Via Benzinga

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

January 30, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

January 23, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

January 13, 2025

From Beam Therapeutics

Via GlobeNewswire

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗

December 20, 2024

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

Via Investor's Business Daily

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 17, 2024

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains ↗

December 09, 2024

Beam Therapeutics unveiled BEAM-101 trial data at ASH, showing improved outcomes in sickle cell patients and promising preclinical BEAM-103 results.

Via Benzinga

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

December 08, 2024

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

December 07, 2024

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

December 06, 2024

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

December 04, 2024

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗

November 26, 2024

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Via Benzinga

Topics Artificial Intelligence

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts ↗

November 25, 2024

Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13.

Via Benzinga

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

November 12, 2024

From Beam Therapeutics

Via GlobeNewswire

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday ↗

November 06, 2024

Via Benzinga

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial ↗

November 05, 2024

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and efficacy results, and progresses on Aalpha-1 Antitrypsin Deficiency

Via Benzinga

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting

November 05, 2024

From Beam Therapeutics

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.